Recursion Pharma is combining high-throughput experimental biology, bioinformatics, and machine learning to rapidly identify new indications for many known drugs and shelved assets. The company completed its IPO [NASDAQ: RXRX] in 2021.

Recursion Pharma is a Salt Lake City-based drug discovery company founded in 2013 based on technology developed at the University of Utah. Recursion uses a novel drug screening platform to efficiently reposition known drugs and shelved pharmaceutical assets to treat rare genetic diseases and other conditions.

• Industry

  • AI & Machine Learning
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2016
  • IPO: 2021

• Founders

  • Chris Gibson, PhD
  • Blake Borgeson, PhD
  • Dean Li, PhD

  LUX Partners

  • Zavain Dar

• Latest Tweets

  • ICYMI: @BiohiveUtah shared @RecursionChris and @Merck Research Labs' Dean Li's fireside chat from #BiohiveSummit https://t.co/vsxQNFrJ58@RecursionPharma - 6h
  • We’re hiring an Automation Support Specialist to discover the root causes of complex electromechanical problems in… https://t.co/5erHLixips@RecursionPharma - 04:13 PM Dec 2nd
  • Today, we announced that Tim Ahfeldt, Ph.D., Irit Rappley, Ph.D. & Glenn Morrison, Ph.D. are joining the Recursion… https://t.co/KwXZrGLIj0@RecursionPharma - 12:57 PM Nov 30th